SER · Serina Therapeutics, Inc.
$1.81
+0.09 (+5.23%)
At close · Oct 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that our existing cash and cash equivalents are not expected to be sufficient to fund our operations for the 12 months following the issuance of our unaudited condensed consolidated financial statements for the period ended June 30, 2026, and that substantial doubt about our ability to continue as a going concern continues to exist.”View the 10-Q filed Aug 13, 2026
Market Cap
$43.69M
Shares
25.40M
Volume · Oct 19
1100
Avg daily vol (3M)
63.97K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.72
Open$1.72
Day$1.72–1.83
52W close$1.28–5.26
Avg vol 30d83K
Short int57K · 0.2% float · 1.0d
Short vol46%
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$21.17M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-48.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+63.8%
Year over year · more shares
Price change (1Y)
-64.8%
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 20 · elevated
Equity put/call 0.65
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
−27%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−4%
trailing
YTD return
−10%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
3 of 27 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.22% of float · ▼ -52.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 2-yr high, broad support
Squeeze score
24
low risk · 0–100
Fundamentals
Revenue growth
+132%
Y/Y
Gross margin
78%
expanding
EPS growth
−26%
Y/Y
Free cash flow
$-18.0M
Balance sheet
$17.5M
net debt
Quant / Vol
risk profile
Volatility
138%
annualized · 1-yr
Max drawdown
−76%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
−27%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
3 of 27 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.22% of float · ▼ -52.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 11%
Range high $5
vs 200-day avg -19%
vs 50-day avg -27%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SER
this stock
Serina Therapeutics, Inc.
|
$43.69M | -10.1% | +132.1% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.66B | +10.2% | +46.2% | 29.1 | 1.8% |
|
MRNA
Moderna, Inc.
|
$87.04B | +639.3% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.41B | +2.4% | +20.8% | 19.6 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.02B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SER | -14.0% | -23.6% | -4.4% | -14.0% | -10.1% |
| SPY | -2.0% | +0.2% | +6.7% | +0.1% | +11.9% |
| vs SPY | -12.0% | -23.8% | -11.2% | -14.1% | -22.0% |